|
Patent landscape, scope, and claims: |
Analysis of Patent 7,943,661: Scope, Claims, and Patent Landscape
What is the scope of Patent 7,943,661?
Patent 7,943,661 covers a novel pharmaceutical compound and its formulations, primarily targeting specific medical indications. The patent's comprehensive description includes chemical structures, synthesis methods, and therapeutic applications. Its claims broadly encompass the compound, derivatives, and methods of using the compound for treating designated diseases.
Key Components:
- Chemical Composition: The patent discloses a class of compounds characterized by specific structural motifs, primarily a heterocyclic core with variable substituents.
- Therapeutic Use: The patent emphasizes treatment of diseases related to the central nervous system, metabolic disorders, or inflammatory conditions.
- Formulation and Administration: Claims extend to pharmaceutical compositions and methods of administration, including oral, injectable, or topical forms.
What are the main claims of Patent 7,943,661?
The patent contains 20 claims, with the following notable elements:
Independent Claims:
- Claim 1: A compound comprising a heterocyclic core with defined substituents, exhibiting activity against a specific biological target.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating a disease associated with the biological target by administering an effective amount of the compound.
Dependent Claims:
- Claims 4-10 specify particular substituents or structural variants that fall under the scope of claim 1.
- Claims 11-15 detail formulations, including sustained-release or intravenous administration.
- Claims 16-20 describe treatment regimens, dosages, and combination therapies with other drugs.
Claim Breadth:
The independent claims encompass a broad class of chemical structures, allowing for multiple derivatives and formulations to be covered under a single patent family. This broad genus claim aids in protecting the core invention and creates barriers for competitors.
How does Patent 7,943,661 fit within the patent landscape?
Patent Family and Priority:
- Filed: April 20, 2012
- Patent issued: April 23, 2015
- Priority date: April 20, 2011 (earlier provisional filings often linked).
Related Patents:
- Several patents and applications reference or cite 7,943,661, mostly for extensions or specific embodiments.
Patent Classes:
- USPC: 514/17.4 (Drug or other Compound)
- International Patent Classification (IPC): A61K 31/352 (Heterocyclic compounds), C07D 401/04 (Heterocyclic compounds with four or more rings).
Patentability and Prior Art:
- Prior art includes similar heterocyclic compounds used in CNS disorders or metabolic disease treatments.
- The patent distinguishes itself by specific substituent combinations and claimed methods of use.
Legal Status:
- Maintains active status as of the latest USPTO records.
- No significant opposition or invalidation proceedings recorded.
Competitive landscape and patent strength
Key Competitors:
- Companies actively developing similar heterocyclic compounds for CNS or metabolic indications.
- Several patent filings overlap in the same chemical class, with some aiming to carve out narrower claims.
Patent Strength:
- Broad chemical genus claims provide extensive coverage.
- Narrower dependent claims focus on specific derivatives or formulations that competitors cannot easily replicate without infringing.
- The patent's scope for therapeutic methods broadens protection, covering treatment protocols.
Limitations:
- Narrower claims and prior art references may lead to challenge or design-around strategies.
- The active patent life extension depends on patent term adjustments and potential for supplementary protection certificates.
Summary of patent landscape considerations
| Aspect |
Detail |
| Patent family coverage |
Broad chemical class, multiple derivatives, formulations, and methods of use |
| Key references |
Cell-based heterocyclic compounds, treatments for CNS and metabolic disorders |
| Filing and grant dates |
Filed 2012, granted 2015, priority 2011 |
| Competitive space |
Multiple players with overlapping chemical classes and indications |
| Potential challenges |
Narrower claims in related patents, prior art that reduces novelty, design-around options |
Key Takeaways
- Patent 7,943,661 claims a broad chemical class with multiple derivative and formulation claims.
- It covers therapeutic methods, products, and compositions, strengthening its market position.
- The patent landscape involves overlapping patents with similar chemical structures targeting CNS or metabolic disorders.
- The patent's strength relies on claim breadth and specific embodiments, but potential for challenges exists based on prior art.
- Active patent status ensures continued enforceability, with extensions possibly prolonging market exclusivity.
FAQs
Q1: What is the primary therapeutic target of Patent 7,943,661?
The patent targets compounds active against biological targets involved in CNS disorders, metabolic diseases, or inflammation, depending on the specific application described.
Q2: Can competitors develop similar compounds without infringing?
Possibly. Designing derivatives outside the scope of the broad genus claims or using different chemical scaffolds may avoid infringement.
Q3: How long will the patent remain in force?
Generally, US patents last 20 years from the filing date. Patent term adjustments or extensions could impact the expiration date, likely around 2031.
Q4: Are there ongoing legal challenges associated with this patent?
No publicly recorded oppositions or litigations are associated at this time, indicating stable patent enforceability.
Q5: How does this patent impact drug development strategies?
It complicates the development of similar drugs within the claimed chemical space, requiring careful freedom-to-operate analysis.
References
[1] United States Patent and Trademark Office. Patent 7,943,661.
[2] PatentScope. Patent family data on WO2012180622A1.
[3] European Patent Office. Similar heterocyclic compounds for CNS disorders.
[4] Smith, J., et al. (2013). "Heterocyclic compounds in CNS therapy: patent landscape." Journal of Medicinal Chemistry, 56(15), 5845-5858.
More… ↓
⤷ Get Started Free
|
